Uroplasty, Inc., based in Minnetonka, Minn., has introduced a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique. Also a Uroplasty product, Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence (SUI) due to intrinsic sphincter deficiency.
The MRN-420 needle is designed to be compatible with most adult cystoscopes. Enhanced needle flexibility provides easier handling and the smaller needle tip helps to control the precise flow and amount of product injected, according to a Uroplasty press release.
“The new, smaller diameter endoscopic needle will increase our access to more urologists and urogynecologists who can now use Macroplastique with their current cystoscope,” said Uroplasty President and CEO David Kaysen.
In a separate development, a new study published in The Journal of Urology (online ahead of print), shows that Macroplastique is effective long-term in women with SUI. The 24-month study evaluated the durability of Macroplastique in women with previously documented success at 12 months. Results showed that 84% of patients had sustained success from 12 to 24 months and 67% of patients were dry at 24 months. Of the 38 patients who were dry at 12 months, 87% maintained their cure at 24 months.